AstraZeneca's Lynparza ups the ante at the PARP table with FDA's speedy breast cancer review
admin 18th October 2017 Uncategorised 0In June, AstraZeneca revealed that in a phase 3 trial, its Lynparza had pared down the risk of disease worsening or death in breast cancer patients by 42%. And that showing apparently impressed the FDA.
More: AstraZeneca's Lynparza ups the ante at the PARP table with FDA's speedy breast cancer review
Source: fierce